IP Library Granted Patent US 12,048,720
Granted Patent B2
US 12,048,720 · App. 16/714,023 · Granted Jul 30, 2024

Compositions comprising bacterial strains

Inventors: Imke Elisabeth Mulder (Aberdeen, GB); Anna Ettorre (Aberdeen, GB); Suaad Ahmed (Aberdeen, GB); Parthena Fotiadou (Aberdeen, GB); Joseph Roby Iringan Urcia (Aberdeen, GB); Helene Savignac (Aberdeen, GB)
Assignee: CJ BIOSCIENCE, INC.
A61K35/74A61K9/0053A61K9/19A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,048,720
App. No.
16/714,023
Granted
Jul 30, 2024
Kind
B2
Abstract

The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

Claims (11)

1. A method of treating a neurodegenerative disorder in a human subject in need thereof, comprising

administering to the human subject a pharmaceutical composition consisting essentially of a single bacteria strain in an amount of 1×10 6 to 1×10 11 CFU/g with respect to a total weight of the pharmaceutical composition,

wherein the neurodegenerative disorder is Parkinson's disease or Alzheimer's disease, and wherein the single bacteria strain is Parabacteroides distasonis having a 16S rRNA gene sequence of SEQ ID NO: 9.

2. The method of claim 1 , wherein the neurodegenerative disorder is an early-onset neurodegenerative disease.

3. The method of claim 1 , wherein the method is a method of delaying an onset or a progression of the neurodegenerative disorder.

4. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

5. The method of claim 1 , wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients or carriers.

6. The method of claim 1 , wherein the single bacteria strain is lyophilized.

7. The method of claim 6 , wherein the lyophilized bacteria strain is live.

8. The method of claim 1 , wherein the neurodegenerative disorder is Alzheimer's disease.

9. The method of claim 1 , wherein the only bacteria in the pharmaceutical composition is the single bacteria strain.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED
To: CJ BIOSCIENCE, INC.
Reel/Frame 063992/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: OXFORD FINANCE LUXEMBOURG S.A R.L.
To: ARMISTICE CAPITAL MASTER FUND LTD.
Reel/Frame 061806/0371 →
INTELECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 30, 2021
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED; 4D PHARMA CORK LIMITED; 4D PHARMA DELAWARE INC.
To: OXFORD FINANCE LUXEMBOURG S.A R.L.
Reel/Frame 057042/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2020
From: MULDER, IMKE ELISABETH; ETTORRE, ANNA; AHMED, SUAAD; FOTIADOU, PARTHENA; URCIA, JOSEPH ROBY IRINGAN; SAVIGNAC, HELENE
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 054438/0648 →
Priority Claims (7)
GB 1709465 · Jun 14, 2017 · national
GB 1709526 · Jun 15, 2017 · national
GB 1805989 · Apr 11, 2018 · national
GB 1805990 · Apr 11, 2018 · national
GB 1805991 · Apr 11, 2018 · national
GB 1806779 · Apr 25, 2018 · national
GB 1806780 · Apr 25, 2018 · national
Continuity (2)
Continuation PCTEP2018065809 · Jun 14, 2018
Related Publication 20200171102A1 · Jun 4, 2020